Trial Profile
Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2019
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Everolimus (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 10 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 17 Dec 2018 Status changed from suspended to active, no longer recruiting.
- 13 Nov 2018 Status changed from recruiting to suspended as per study design.